Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional webinar was initiated and fully funded by AstraZeneca. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.

Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance

This promotional webinar was initiated and fully funded by AstraZeneca. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com or by calling 0800 783 0033.

GB 27621 | March 2021

Thank you for registering.

We look forward to welcoming you online. You will receive a confirmation email shortly and we will send you a reminder email closer to the start of the broadcast.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.